Loading...
Emergent BioSolutions Q1 2025 Earnings Report
Emergent BioSolutions reported a decrease in total revenues but a significant increase in net income for the first quarter of 2025.
Key Takeaways
Emergent BioSolutions reported a 26% decrease in total revenues to $222.2 million for Q1 2025 compared to Q1 2024, but net income surged by 656% to $68.0 million. The company's gross margin expanded to 50%, and adjusted EBITDA increased by 16% to $77.6 million, demonstrating improved profitability despite lower sales.
Total revenues decreased by 26% to $222.2 million in Q1 2025 compared to Q1 2024.
Net income increased by 656% to $68.0 million in Q1 2025 compared to Q1 2024.
Adjusted EBITDA increased by 16% to $77.6 million in Q1 2025 compared to Q1 2024.
Gross Margin % expanded to 50% and Adjusted Gross Margin % to 58% in Q1 2025.
Revenue by Segment
Forward Guidance
Emergent BioSolutions reaffirmed its full-year 2025 guidance, with total revenues expected to remain between $750 million and $850 million. The company anticipates increased net income and maintains its outlook for adjusted net income, adjusted EBITDA, and adjusted gross margin percentage.
Positive Outlook
- Total revenues guidance reaffirmed at $750-$850 million for FY 2025.
- Net income guidance increased to $20-$70 million for FY 2025.
- Adjusted net income guidance reaffirmed at $20-$70 million for FY 2025.
- Adjusted EBITDA guidance reaffirmed at $150-$200 million for FY 2025.
- Adjusted gross margin % guidance reaffirmed at 48%-51% for FY 2025.
Challenges Ahead
- No specific negative adjustments or revised downward forecasts were provided in the guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...